Non syndromic neuroendocrine tumors
Showing 1 - 25 of >10,000
Non-functional Neuroendocrine Tumors of Pancreatic Body and Tail
Recruiting
- Non Functioning Pancreatic Endocrine Tumor
- Histopathological review, long-term prognosis and quality of life follow-up
-
Shanghai, Shanghai, ChinaDepartment of Pancreatic Surgery, Fudan University Shanghai Canc
Jun 8, 2023
EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine Trial run by the National Cancer Institute (NCI)
Recruiting
- EGFR-Mutated Non-Small-Cell Lung Carcinoma
- Small Cell/Neuroendocrine
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours Trial in Worldwide (lanreotide, Placebo)
Terminated
- Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours
- lanreotide
- Placebo
-
Bruxelles, Belgium
- +23 more
Dec 21, 2022
Neuroendocrine Tumors Trial in Sweden (177Lu-DOTATOC, Capecitabine)
Not yet recruiting
- Neuroendocrine Tumors
-
Göteborg, Sweden
- +3 more
May 19, 2022
Advanced Lung Carcinoid Tumor, Functioning Lung Carcinoid Tumor, Locally Advanced Lung Neuroendocrine Tumor Trial in Boston,
Recruiting
- Advanced Lung Carcinoid Tumor
- +11 more
- Everolimus
- Lutetium Lu 177 Dotatate
-
Boston, Massachusetts
- +1 more
Jul 19, 2022
Neuroendocrine Tumors Trial in Australia (64Cu-SARTATE)
Recruiting
- Neuroendocrine Tumors
-
Kingswood, New South Wales, Australia
- +3 more
May 17, 2022
Small Cell Lung Carcinoma (SCLC), Neuroendocrine Tumors Trial (BI 764532, Ezabenlimab)
Not yet recruiting
- Small Cell Lung Carcinoma (SCLC)
- Neuroendocrine Neoplasms
- BI 764532
- Ezabenlimab
- (no location specified)
May 25, 2023
Breast Cancer, Neuroendocrine Tumors, Neuroendocrine Carcinoma Trial in Copenhagen (18F-FDG, Injection of hyperpolarized
Enrolling by invitation
- Breast Cancer
- +3 more
- 18F-FDG
- +2 more
-
Copenhagen, DenmarkRigshospitalet
Jan 18, 2023
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Chang chun
Not yet recruiting
- RET-altered Non Small Cell Lung Cancer
- +3 more
-
Chang chun, Jilin, ChinaJinlin Province Cancer Hosipital
Dec 21, 2022
Neuroendocrine Tumors, Neuroendocrine Carcinoma, Pancreas Tumor Trial in Roma, Rome (EUS guided radiofrequency ablation)
Recruiting
- Neuroendocrine Tumors
- +3 more
- EUS guided radiofrequency ablation
-
Roma, RM, Italy
- +1 more
Feb 10, 2022
Metastatic Lung Neuroendocrine Tumor, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma Trial in
Active, not recruiting
- Metastatic Lung Neuroendocrine Neoplasm
- +6 more
- Berzosertib
- +3 more
-
Duarte, California
- +8 more
Jul 16, 2022
Genitourinary Cancer, Adrenocortical Carcinoma, Non-urothelial Bladder Trial in United States (Ipilimumab, Nivolumab)
Recruiting
- Genitourinary Cancer
- +7 more
-
La Jolla, California
- +5 more
Jul 5, 2022
Small Cell Carcinoma, NSCLC, Neuroendocrine Tumors Trial in United States (RRx-001, Cisplatin, Etoposide)
Active, not recruiting
- Small Cell Carcinoma
- +3 more
- RRx-001
- +11 more
-
Palo Alto, California
- +9 more
May 12, 2022
Pulmonary Neuroendocrine Tumor, Pheochromocytoma, Paraganglioma Trial in Houston (177Lu-DOTATOC)
Recruiting
- Pulmonary Neuroendocrine Neoplasm
- +9 more
-
Houston, TexasExcel Diagnostics and Nuclear Oncology Center
Jul 9, 2021
Viewpoints on Social Representations and Rationale Concerning
Terminated
- Non-resectable Metastatic Cancer of the Lung
- +7 more
- Interviews
- Questionnaires
-
Dijon, FranceChu Dijon Bourogne
Apr 14, 2022
Lung Atypical Carcinoid Tumor, Lung Neuroendocrine Tumor, Lung Non-Small Cell Squamous Carcinoma Trial in Conroe, Houston
Recruiting
- Lung Atypical Carcinoid Tumor
- +13 more
- Nivolumab
- Stereotactic Body Radiation Therapy
-
Conroe, Texas
- +2 more
Feb 25, 2022
A Multi Biomarker Approach In Metastatic GEP NETs
Completed
- Gastroenteropancreatic Neuroendocrine Tumors
- This is a non-interventional study. Patients will be treated with any intervention deemed appropriate by the patient's physician.
-
Aarhus, Denmark
- +24 more
Dec 6, 2021
Sunitinib In Chinese Progressive Advanced Or Metastatic
Active, not recruiting
- Pancreatic Neuroendocrine Tumors
-
Hefei, Anhui, China
- +15 more
Oct 19, 2021
Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma Trial in France (Phase 1 : Regorafenib,
Recruiting
- Colorectal Cancer Not MSI-H or MMR-deficient
- +9 more
- Phase 1 : Regorafenib
- +4 more
-
Bordeaux, France
- +6 more
Dec 6, 2021
Neuroendocrine Tumors, Non-hematologic Malignancy Trial in Japan (Surufatinib)
Recruiting
- Neuroendocrine Tumors
- Non-hematologic Malignancy
-
Fukuoka, Japan
- +11 more
Feb 1, 2022
Neuroendocrine Tumor, Carcinoid Syndrome Trial in Nashville (Enterade®, Functional Assessment of Chronic Illness Therapy for
Terminated
- Neuroendocrine Tumor
- Carcinoid Syndrome
- Enterade®
- Functional Assessment of Chronic Illness Therapy for Patients with Diarrhea (version 4.0)
-
Nashville, TennesseeVanderbilt-Ingram Cancer Center
May 18, 2021
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide
Active, not recruiting
- RET-altered Non Small Cell Lung Cancer
- +39 more
- pralsetinib (BLU-667)
-
Phoenix, Arizona
- +65 more
Nov 10, 2022
Melanoma, Breast Carcinoma, Hepatocellular Carcinoma Trial in United States (XmAb20717)
Completed
- Melanoma
- +27 more
- XmAb20717
-
Los Angeles, California
- +16 more
Nov 29, 2022